A randomized study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. metastatic breast cancer: HER2CLIMB
Müller V, Park-Simon T, Huober J, Schmidt M, Weide R, Reinisch M, Fehm T, Salat C, Loibl S, Mundhenke C, Winer E. A randomized study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. metastatic breast cancer: HER2CLIMB. Geburtshilfe Und Frauenheilkunde 2018, 78: 245-245. DOI: 10.1055/s-0038-1671504.Peer-Reviewed Original Research